Northwest Biotherapeutics (OTCMKTS:NWBO – Get Free Report) issued its quarterly earnings data on Friday. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, Zacks reports.
Northwest Biotherapeutics Stock Performance
OTCMKTS:NWBO traded down $0.01 during trading hours on Friday, reaching $0.16. The company’s stock had a trading volume of 4,713,982 shares, compared to its average volume of 3,421,022. The stock has a 50 day moving average price of $0.16 and a two-hundred day moving average price of $0.20. The company has a market capitalization of $285.45 million, a P/E ratio of -0.01 and a beta of -0.59. Northwest Biotherapeutics has a 12 month low of $0.14 and a 12 month high of $0.34.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company developing immunotherapies for cancer, with a focus on treatments made from a patient’s own immune cells. Its platform uses dendritic cells, which can help the immune system recognize and respond to cancer. The company’s lead product candidate, DCVax-L, is a personalized dendritic-cell therapy being developed for glioblastoma, an aggressive form of brain cancer. Northwest Biotherapeutics has also developed DCVax-Direct, an investigational therapy designed to be injected into tumors.
Featured Stories
- Five stocks we like better than Northwest Biotherapeutics
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
